Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.

Cañamares-Orbis I, Merino L, López J, Llorente I, García-Vadillo A, Ramirez E, López-Bote JP, Benedí J, Muñoz-Calleja C, Álvaro-Gracia JM, Castañeda S, González-Álvaro I.

J Clin Rheumatol. 2018 Jul 19. doi: 10.1097/RHU.0000000000000845. [Epub ahead of print]

2.

Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus.

González-Serna D, Ortiz-Fernández L, Vargas S, García A, Raya E, Fernández-Gutierrez B, López-Longo FJ, Balsa A, González-Álvaro I, Narvaez J, Gómez-Vaquero C, Sabio JM, García-Portales R, González-Escribano MF, Tolosa C, Carreira P, Kiemeney L, Coenen MJH, Witte T, Schneider M, González-Gay MÁ, Martín J.

Sci Rep. 2018 May 29;8(1):8195. doi: 10.1038/s41598-018-26573-4.

3.

Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.

López-Rodríguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A, Świerkot J, Slezak R, Dolžan V, González-Álvaro I, Narváez J, Cáliz R, Pérez-Pampín E, Mera-Varela A, Vidal-Bralo L, Acuña Ochoa JG, Conde C, Gómez-Reino JJ, González A.

Sci Rep. 2018 May 9;8(1):7342. doi: 10.1038/s41598-018-25634-y.

4.

Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.

López-Rodríguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A, Świerkot J, Slezak R, Gonzalez-Alvaro I, Narvaez J, Pérez-Pampín E, Mera-Varela A, Vidal-Bralo L, Acuña-Ochoa JG, Conde C, Gonzalez A.

Pharmacogenomics J. 2018 Mar 8. doi: 10.1038/s41397-018-0017-5. [Epub ahead of print]

PMID:
29520081
5.

Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.

Municio C, Dominguez-Soto Á, Fuentelsaz-Romero S, Lamana A, Montes N, Cuevas VD, Campos RG, Pablos JL, González-Álvaro I, Puig-Kröger A.

Ann Rheum Dis. 2018 May;77(5):752-759. doi: 10.1136/annrheumdis-2017-212537. Epub 2018 Feb 3.

6.

Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.

Seoane IV, Martínez C, García-Vicuña R, Ortiz AM, Juarranz Y, Talayero VC, González-Álvaro I, Gomariz RP, Lamana A.

Sci Rep. 2018 Feb 1;8(1):2035. doi: 10.1038/s41598-018-20400-6.

7.

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.

González-Álvaro I, Blasco AJ, Lázaro P, Sánchez-Piedra C, Almodovar R, Bachiller-Corral J, Balsa A, Caliz R, Candelas G, Fernández-Carballido C, García-Aparicio A, García-Magallón B, García-Vicuña R, Gómez-Centeno A, Ortiz AM, Sanmartí R, Sanz J, Tejera B.

Heliyon. 2017 Nov 14;3(11):e00452. doi: 10.1016/j.heliyon.2017.e00452. eCollection 2017 Nov.

8.

Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study.

Toledano E, Ortiz AM, Ivorra-Cortes J, Montes N, Beltran A, Rodríguez-Rodriguez L, Carmona L, González-Álvaro I.

Clin Exp Rheumatol. 2018 May-Jun;36(3):382-388. Epub 2017 Nov 28.

PMID:
29185958
9.

[Medullar thoracic compression by tophaceous gout: presentation of a case and review of the literature].

Arevalo-Saenz A, Gonzalez-Alvaro I, Pulido-Rivas P, Vicente E, Garcia E, Castaneda S, Ocon E, Gomez-Leon N, Sola RG.

Rev Neurol. 2017 Oct 16;65(8):368-372. Spanish.

10.

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.

Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, González A.

Sci Rep. 2017 Sep 20;7(1):12023. doi: 10.1038/s41598-017-09657-5.

11.

Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach.

Lezcano-Valverde JM, Salazar F, León L, Toledano E, Jover JA, Fernandez-Gutierrez B, Soudah E, González-Álvaro I, Abasolo L, Rodriguez-Rodriguez L.

Sci Rep. 2017 Aug 31;7(1):10189. doi: 10.1038/s41598-017-10558-w.

12.

Severity indices in rheumatoid arthritis: A systematic review.

Toledano E, García de Yébenes MJ, González-Álvaro I, Carmona L.

Reumatol Clin. 2017 Aug 11. pii: S1699-258X(17)30180-8. doi: 10.1016/j.reuma.2017.07.004. [Epub ahead of print] English, Spanish.

14.

Novelties in the therapeutic scene of rheumatoid arthritis.

Castañeda S, González-Álvaro I.

Reumatol Clin. 2017 Mar - Apr;13(2):63-65. doi: 10.1016/j.reuma.2017.02.001. English, Spanish. No abstract available.

15.

mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis.

Castro-Sánchez P, Ramirez-Munoz R, Lamana A, Ortiz A, González-Álvaro I, Roda-Navarro P.

Clin Exp Immunol. 2017 Jul;189(1):113-119. doi: 10.1111/cei.12953. Epub 2017 Mar 28. Erratum in: Clin Exp Immunol. 2018 Feb;191(2):252.

16.

Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients.

Llorente I, Merino L, Ortiz AM, Escolano E, González-Ortega S, García-Vicuña R, García-Vadillo JA, Castañeda S, González-Álvaro I.

Rheumatol Int. 2017 May;37(5):799-806. doi: 10.1007/s00296-017-3674-9. Epub 2017 Feb 27.

17.

Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis.

López-Mejías R, Corrales A, Vicente E, Robustillo-Villarino M, González-Juanatey C, Llorca J, Genre F, Remuzgo-Martínez S, Dierssen-Sotos T, Miranda-Filloy JA, Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Ferraz-Amaro I, Gómez-Vaquero C, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I, Ocejo-Vinyals JG, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2017 Jan 6;7:40303. doi: 10.1038/srep40303.

18.

Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity.

Sala-Icardo L, Lamana A, Ortiz AM, García Lorenzo E, Moreno Fresneda P, García-Vicuña R, González-Álvaro I.

Reumatol Clin. 2017 Nov - Dec;13(6):318-325. doi: 10.1016/j.reuma.2016.08.006. Epub 2016 Oct 15. English, Spanish.

19.

Influence of patient personality in the treatment of rheumatoid arthritis.

Leon L, Redondo M, Garcia-Vadillo A, Perez-Nieto MA, Rodriguez-Rodriguez L, Jover JA, Gonzalez-Alvaro I, Abasolo L.

Rheumatol Int. 2016 Nov;36(11):1549-1555. Epub 2016 Sep 10.

PMID:
27614619
20.

Urine metabolome profiling of immune-mediated inflammatory diseases.

Alonso A, Julià A, Vinaixa M, Domènech E, Fernández-Nebro A, Cañete JD, Ferrándiz C, Tornero J, Gisbert JP, Nos P, Casbas AG, Puig L, González-Álvaro I, Pinto-Tasende JA, Blanco R, Rodríguez MA, Beltran A, Correig X, Marsal S; IMID Consortium.

BMC Med. 2016 Sep 8;14(1):133. doi: 10.1186/s12916-016-0681-8.

21.

Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis.

González-Álvaro I, Castrejón I, Ortiz AM, Toledano E, Castañeda S, García-Vadillo A, Carmona L; EMECAR Study Group.

PLoS One. 2016 Sep 7;11(9):e0161727. doi: 10.1371/journal.pone.0161727. eCollection 2016.

22.

Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.

López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, Tejera-Segura B, Ramírez Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Mínguez Sánchez MD, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2016 Aug 18;6:31979. doi: 10.1038/srep31979.

23.

Comparative analysis of EV isolation procedures for miRNAs detection in serum samples.

Andreu Z, Rivas E, Sanguino-Pascual A, Lamana A, Marazuela M, González-Alvaro I, Sánchez-Madrid F, de la Fuente H, Yáñez-Mó M.

J Extracell Vesicles. 2016 Jun 20;5:31655. doi: 10.3402/jev.v5.31655. eCollection 2016.

24.

A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus.

Márquez A, Vidal-Bralo L, Rodríguez-Rodríguez L, González-Gay MA, Balsa A, González-Álvaro I, Carreira P, Ortego-Centeno N, Ayala-Gutiérrez MM, García-Hernández FJ, González-Escribano MF, Sabio JM, Tolosa C, Suárez A, González A, Padyukov L, Worthington J, Vyse T, Alarcón-Riquelme ME, Martín J.

Ann Rheum Dis. 2017 Jan;76(1):286-294. doi: 10.1136/annrheumdis-2016-209436. Epub 2016 May 18.

PMID:
27193031
25.

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.

Ortea I, Roschitzki B, López-Rodríguez R, Tomero EG, Ovalles JG, López-Longo J, de la Torre I, González-Alvaro I, Gómez-Reino JJ, González A.

PLoS One. 2016 Apr 6;11(4):e0153140. doi: 10.1371/journal.pone.0153140. eCollection 2016.

26.

Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis.

Municio C, Soler Palacios B, Estrada-Capetillo L, Benguria A, Dopazo A, García-Lorenzo E, Fernández-Arroyo S, Joven J, Miranda-Carús ME, González-Álvaro I, Puig-Kröger A.

Ann Rheum Dis. 2016 Dec;75(12):2157-2165. doi: 10.1136/annrheumdis-2015-208736. Epub 2016 Feb 26.

PMID:
26920997
27.

Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.

Seoane IV, Ortiz AM, Piris L, Lamana A, Juarranz Y, García-Vicuña R, González-Álvaro I, Gomariz RP, Martínez C.

PLoS One. 2016 Feb 16;11(2):e0149141. doi: 10.1371/journal.pone.0149141. eCollection 2016.

28.

VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts.

Pérez-García S, Carrión M, Gutiérrez-Cañas I, González-Álvaro I, Gomariz RP, Juarranz Y.

J Cell Mol Med. 2016 Apr;20(4):678-87. doi: 10.1111/jcmm.12777. Epub 2016 Jan 28.

29.

Identification of IRX1 as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study.

Julià A, Blanco F, Fernández-Gutierrez B, González A, Cañete JD, Maymó J, Alperi-López M, Olivè A, Corominas H, Martínez-Taboada V, González-Álvaro I, Fernandez-Nebro A, Erra A, Sánchez-Fernández S, Alonso A, López-Lasanta M, Tortosa R, Codó L, Lluis Gelpi J, García-Montero AC, Bertranpetit J, Absher D, Myers RM, Tornero J, Marsal S.

Arthritis Rheumatol. 2016 Jun;68(6):1384-91. doi: 10.1002/art.39591.

30.

The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression.

Lamana A, López-Santalla M, Castillo-González R, Ortiz AM, Martín J, García-Vicuña R, González-Álvaro I.

PLoS One. 2015 Nov 16;10(11):e0142683. doi: 10.1371/journal.pone.0142683. eCollection 2015.

31.

PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts.

Rodriguez-Rodriguez L, Ivorra-Cortes J, Carmona FD, Martín J, Balsa A, van Steenbergen HW, van der Helm-van Mil AH, González-Álvaro I, Fernandez-Gutiérrez B.

Arthritis Res Ther. 2015 Nov 5;17:306. doi: 10.1186/s13075-015-0830-z.

32.

Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis.

Lopez-Lasanta M, Julià A, Maymó J, Fernández-Gutierrez B, Ureña-Garnica I, Blanco FJ, Cañete JD, Alperi-López M, Olivè A, Corominas H, Tornero J, Erra A, Almirall M, Palau N, Ortiz A, Avila G, Rodriguez-Rodriguez L, Alonso A, Tortosa R, Gonzalez-Alvaro I, Marsal S.

Arthritis Res Ther. 2015 Sep 4;17:242. doi: 10.1186/s13075-015-0737-8.

33.

[Rheumatoid arthritis at present].

González-Álvaro I, García-Vicuña R.

Med Clin (Barc). 2016 Feb 5;146(3):112-4. doi: 10.1016/j.medcli.2015.06.004. Epub 2015 Jul 27. Spanish. No abstract available.

PMID:
26228258
34.

2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, Fernández-Nebro A, Ferraz-Amaro I, Gómez-Reino JJ, González-Álvaro I, Martín-Mola E, Martínez-Taboada VM, Ortiz AM, Tornero J, Marsal S, Moreno-Muelas JV.

Reumatol Clin. 2015 Sep-Oct;11(5):279-94. doi: 10.1016/j.reuma.2015.05.001. Epub 2015 Jun 6. English, Spanish.

35.

Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis.

Avila-Pedretti G, Tornero J, Fernández-Nebro A, Blanco F, González-Alvaro I, Cañete JD, Maymó J, Alperiz M, Fernández-Gutiérrez B, Olivé A, Corominas H, Erra A, Aterido A, López Lasanta M, Tortosa R, Julià A, Marsal S.

PLoS One. 2015 Apr 7;10(4):e0122088. doi: 10.1371/journal.pone.0122088. eCollection 2015.

36.

Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity.

Seoane IV, Tomero E, Martínez C, Garcia-Vicuña R, Juarranz Y, Lamana A, Ocón E, Ortiz AM, Gómez-León N, González-Álvaro I, Gomariz RP.

J Mol Neurosci. 2015 Jul;56(3):577-84. doi: 10.1007/s12031-015-0517-6. Epub 2015 Feb 25.

37.

Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis.

Loza E, Lajas C, Andreu JL, Balsa A, González-Álvaro I, Illera O, Jover JÁ, Mateo I, Orte J, Rivera J, Rodríguez Heredia JM, Romero F, Martínez-López JA, Ortiz AM, Toledano E, Villaverde V, Carmona L, Castañeda S.

Rheumatol Int. 2015 Mar;35(3):445-58. doi: 10.1007/s00296-014-3196-7. Epub 2014 Dec 28. Review.

PMID:
25543267
38.

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S; Spanish Rheumatology Society; Spanish Rheumatology Society.

Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461. Epub 2014 Dec 19.

39.

The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP.

Jimeno R, Gomariz RP, Garín M, Gutiérrez-Cañas I, González-Álvaro I, Carrión M, Galindo M, Leceta J, Juarranz Y.

J Mol Med (Berl). 2015 Apr;93(4):457-67. doi: 10.1007/s00109-014-1232-4. Epub 2014 Nov 28.

40.

Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile.

Soler Palacios B, Estrada-Capetillo L, Izquierdo E, Criado G, Nieto C, Municio C, González-Alvaro I, Sánchez-Mateos P, Pablos JL, Corbí AL, Puig-Kröger A.

J Pathol. 2015 Feb;235(3):515-26. doi: 10.1002/path.4466. Epub 2014 Dec 18.

PMID:
25319955
41.

Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study.

Ferreiro-Iglesias A, Calaza M, Perez-Pampin E, Lopez Longo FJ, Marenco JL, Blanco FJ, Narvaez J, Navarro F, Cañete JD, de la Serna AR, Gonzalez-Alvaro I, Herrero-Beaumont G, Pablos JL, Balsa A, Fernandez-Gutierrez B, Caliz R, Gomez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2014 Sep 27;16(5):436. doi: 10.1186/s13075-014-0436-x.

42.

Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis.

Genre F, López-Mejías R, García-Bermúdez M, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2014 Sep 3;9(9):e106823. doi: 10.1371/journal.pone.0106823. eCollection 2014.

43.

Biomarkers predicting a need for intensive treatment in patients with early arthritis.

González-Álvaro I, Ortiz AM, Seoane IV, García-Vicuña R, Martínez C, Gomariz RP.

Curr Pharm Des. 2015;21(2):170-81. Review.

44.

Thematic issue: optimizing treatment in rheumatoid arthritis.

Gomariz RP, Gonzalez-Alvaro I.

Curr Pharm Des. 2015;21(2):129. No abstract available.

PMID:
25163733
45.

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides.

Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, Tak PP, Posthumus MD, Wijmenga C, Huizinga T, van der Helm-van Mil AH, Stoeken-Rijsbergen G, Rodriguez-Rodriguez L, Balsa A, González-Álvaro I, González-Gay MÁ, Gómez-Vaquero C, Franke B; LifeLines Cohort Study, Vermeulen S, van der Horst-Bruinsma Ie, Dijkmans BA, Wolbink GJ, Ophoff RA, Maehlen MT, van Riel P, Merriman M, Klareskog L, Lie BA, Merriman T, Crusius JB, Brouwer E, Martin J, de Vries N, Toes R, Padyukov L, Koeleman BP.

Ann Rheum Dis. 2015 Mar;74(3):e15. doi: 10.1136/annrheumdis-2013-204591. Epub 2014 Feb 14.

PMID:
24532677
46.

Single-nucleotide polymorphisms at the 9p21.3 genomic region not associated with the risk of cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

Tissue Antigens. 2013 Dec;82(6):405-9. doi: 10.1111/tan.12227. Epub 2013 Oct 15.

PMID:
24498997
47.

Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis.

Martínez C, Ortiz AM, Juarranz Y, Lamana A, Seoane IV, Leceta J, García-Vicuña R, Gomariz RP, González-Álvaro I.

PLoS One. 2014 Jan 7;9(1):e85248. doi: 10.1371/journal.pone.0085248. eCollection 2014.

48.

Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.

Pérez-García S, Carrión M, Jimeno R, Ortiz AM, González-Álvaro I, Fernández J, Gomariz RP, Juarranz Y.

J Mol Neurosci. 2014 Jan;52(1):18-27. doi: 10.1007/s12031-013-0189-z. Epub 2013 Dec 7.

PMID:
24318839
49.

VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction.

Carrión M, Juarranz Y, Seoane IV, Martínez C, González-Álvaro I, Pablos JL, Gutiérrez-Cañas I, Gomariz RP.

J Mol Neurosci. 2014 Jan;52(1):10-7. doi: 10.1007/s12031-013-0177-3. Epub 2013 Nov 20.

PMID:
24254222
50.

SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Rueda-Gotor J, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2013 Oct 21;8(10):e77695. doi: 10.1371/journal.pone.0077695. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/3fc037c1-2585-4d2b-a781-e04ab7b3bfeb.

Supplemental Content

Loading ...
Support Center